StockData

Lexaria Bioscience vs Serina Therapeutics

LEXX and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

lexxLexaria Bioscience$4.44−74.0% in 1 yearserSerina Therapeutics$1.39−65.4% in 1 year

How LEXX and SER compare

Lexaria Bioscience is the larger company, worth 3.1 times as much as Serina Therapeutics ($110M against $35.3M).

Lexaria Bioscience scores higher on the StockData Score (8 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLEXXSER
Size and price
Market cap$110M$35.3M
Share price$4.44$1.39
Change, 1 year−74.0%−65.4%
Change, 5 years−94.7%−95.0%
Beta (5Y)0.820.35
Employees13416
StockData Score
Total score8 (better)2
Valuation score00
Growth score2 (better)1
Performance score00
Health score6 (better)1
Dividend score00
Valuation
P/S567×–
P/B23.2×2.5× (better)
FCF yield−6.8% (better)−64.7%
Growth
Revenue growth (TTM)−68.5%–
Revenue growth, 5Y average17.5% (better)−18.5%
Profitability
Gross margin100%–
Operating margin−3973%–
Net margin−3986%–
FCF margin−3849%–
Return on equity−150% (better)−312%
Return on invested capital−602%–
Financial health
Debt / equity0.00–
Current ratio10.60 (better)4.62
Altman Z-score126.66 (better)−1.86
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield−5.9%–
Shareholder yield−5.9%0.00% (better)
Ownership
Held by institutions–5.5%
Held by insiders3.0%49.7%
Insider net buying, 12 months–−$232K
Short interest, % of float0.90%0.37%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.